Search clinical trials for: Taxotere®

Total 14353 results

Hoffmann-La Roche

Completed

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China, United States, South Africa, Russian Federation, Thailand, Bosnia and Herzegovina, Czech Republic, India, Poland
National University Hospital, Singapore

Completed

Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle

Solid Tumors

Singapore
Hospira, now a wholly owned subsidiary of Pfizer

Completed

The Pharmacokinetics and Safety Characteristics of Docetaxel in Patients With Cancer

Cancer

United Kingdom, Russian Federation
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Completed

Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
University Hospital, Limoges
Groupe Francais De Pneumo-Cancerologie

Completed

Pharmaco-economic Study of a Second Line Treatment in Advanced Non Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

France
Washington University School of Medicine
Sanofi

Terminated

Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma

Ovarian Cancer

United States
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Not yet recruiting

Substudy 01A: Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC

Completed

Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

Non Small Cell Lung Cancer (NSCLC)
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States
Washington University School of Medicine
National Cancer Institute (NCI); National Institutes of Health (NIH); Breast... and other collaborators

Terminated

Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

Triple Negative Breast Neoplasms

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)

Nasopharyngeal Neoplasms
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer (ENTHUSE M1C)

Prostate Cancer

Sweden, United States, Brazil, France, Peru, Spain, United Kingdom, Germany, Poland, Romania, Finland, Canada, Argentina, Australia, South Africa, Czech Republic, India, Netherlands, Italy, Switzerland, Korea, Republic of, Hungary, ... and more
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)

Carcinoma, Non-Small-Cell Lung
Genzyme, a Sanofi Company

Completed

E3 Breast Cancer Taxotere Combination

Advanced Breast Cancer

South Africa, Sweden, Hungary, Taiwan, Spain
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia

Leukemia

United States, Canada, Australia, Switzerland, Puerto Rico, Netherlands, New Zealand
AstraZeneca

Completed

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Prostate Cancer

United Kingdom, Germany, United States
Merck Sharp & Dohme LLC
GOG Foundation; European Network of Gynaecological Oncological Trial Groups...

Active, not recruiting

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Endometrial Neoplasms

Australia, United States, Germany, Israel, Korea, Republic of, Poland, Turkey, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, Hungary, Ireland, Italy, Japan, Netherlands, New Zealand, Norway, Russian Federation, Spain, Swed... and more
Institut de Recherches Internationales Servier

Terminated

Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss

Lymphoma | Advanced Solid Tumors

United States, Spain, France
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)

Breast Cancer | Gastric Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer
Bristol-Myers Squibb

Recruiting

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, Italy, Canada, Australia, France, Argentina, Mexico, Chile
Merck Sharp & Dohme LLC

Completed

A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)

Locally Advanced, Metastatic Solid Tumors
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
University of Michigan Rogel Cancer Center

Terminated

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Cancer of Larynx

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

Metastatic Non-Small Cell Lung Cancer

Russian Federation, Australia, United States, Argentina, Canada, Colombia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Portugal, Puerto Rico, Spain, United Kingdom
Hoffmann-La Roche

Completed

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Non-small Cell Lung Cancer

Belgium, Italy, Portugal, Spain, Germany, Turkey, France, Hong Kong, Korea, Republic of, Poland, Russian Federation, Hungary, Norway, Bulgaria, Slovakia
Mallinckrodt

Withdrawn

Safety and Efficacy Study of Acthar in Subjects With ARDS

Acute Respiratory Distress Syndrome
Gilead Sciences

Active, not recruiting

Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC)

Solid Tumor

Spain, United Kingdom, United States, France, Poland
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study

Esophageal Carcinoma | Esophagogastric Junction Carcinoma

China
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

Esophageal Carcinoma | Esophagogastric Junction Carcinoma
Sanofi

Completed

Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy (TFINE)

Lung Neoplasms

China
Karyopharm Therapeutics Inc

Recruiting

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment (SPRINT)

Other Solid Tumors | Colorectal Cancer (CRC) | Non-Small Cell Lung Carcinoma (NSCLC)

Israel
M.D. Anderson Cancer Center
Genentech, Inc.

Active, not recruiting

OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer

Head and Neck Cancer

United States
Pfizer

Completed

A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)

Early Breast Cancer

Czechia, Serbia, Slovakia, United States, Belarus, Hungary, Ukraine, Italy, Poland, Russian Federation
Bristol-Myers Squibb

Completed

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Advanced Cancer

United States, Canada
University Hospital, Limoges
Boehringer Ingelheim

Completed

Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer (REFRACT)

Lung Neoplasms

France
Kyowa Kirin, Inc.

Completed

Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Sanofi

Completed

TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary (TEACO)

Ovarian Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Docetaxel in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma

United States
Fudan University

Unknown

Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer

Breast Neoplasms | Chemotherapy | Adjuvant

China
Gilead Sciences
Everest Medicines

Active, not recruiting

Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04)

Locally Advanced or Metastatic Unresectable Urothelial Cancer

United States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Squamous Cell Carcinoma of Head and Neck

United States, Australia, Canada, Denmark, France, Israel, Korea, Republic of, Portugal, Romania, Spain, Taiwan, United Kingdom, Colombia, Brazil, Norway
Susanne Crocamo

Completed

ZoNantax - Zolendronic Acid as Neoadjuvant Therapy Plus Anthracycline and Taxane in Locally Advanced Breast Cancer

Neoplasms | Neoplasms by Site | Breast Cancer | Breast Disease

Brazil
NewLink Genetics Corporation

Terminated

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Recurrent | Progression of Non-small Cell Lung Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Active, not recruiting

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Stage IV Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage IIIB | EGFR Negative Non-Small Cell Lung Cancer

United States
Centre Antoine Lacassagne

Completed

Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer (TAXOMET)

Prostatic Neoplasms

France
Bristol-Myers Squibb

Completed

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)

Squamous Cell Non-small Cell Lung Cancer

United States, France, Chile, Australia, Netherlands, Argentina, Austria, Canada, Czechia, Germany, Hungary, Ireland, Italy, Mexico, Norway, Peru, Poland, Romania, Russian Federation, Spain, United Kingdom
Mirati Therapeutics Inc.

Terminated

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stomach Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Prostate Cancer | Non-Small-Cell Lung Carcinoma | Prostatic Cancer | Pulmonary Cancer

United States
Robert Morris
National Cancer Institute (NCI)

Completed

Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer

Ovarian Cancer | Peritoneal Cavity Cancer

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer

Gastric Cancer
Nereus Pharmaceuticals, Inc.

Completed

Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer

Cancer

United States, Australia, India, Chile, Brazil, Argentina

Search clinical trials for: Taxotere®

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations